3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
44
Neoplasms, Plasma Cell
10
Neoplasms
3
Vomiting
2
Recurrence
2
Lung Neoplasms
2
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Nausea
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
Gemcitabine
74
Fluorouracil
31
Oxaliplatin
21
Leucovorin
21
130-nm albumin-bound paclitaxel
17
Capecitabine
14
Irinotecan
12
Albumin-Bound Paclitaxel
10
irinotecan sucrosofate
8
Radiotherapy
6
Taxes
5
Erlotinib Hydrochloride
5
folfirinox
4
rubitecan
3
Surgical Procedures, Operative
3
Specimen Handling
3
Pancreaticojejunostomy
3
Neoadjuvant Therapy
3
Drug Therapy
3
Cisplatin
3
Chemotherapy, Adjuvant
3
ruxolitinib
2
masitinib
2
dehydroftorafur
2
Saline Solution
2
S 1 (combination)
2
Paclitaxel
2
GV1001 peptide
2
Fentanyl
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Pancreatic Neoplasms
×
Thalidomide
×
Clear all
NCT06017284
2023-11-24
PTCA199-5
Fudan University
Phase 3
Recruiting
100 enrolled